216 related articles for article (PubMed ID: 37152424)
1. The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review.
Martin FC; Dorff TB; Tran B
Ther Adv Med Oncol; 2023; 15():17588359231170474. PubMed ID: 37152424
[TBL] [Abstract][Full Text] [Related]
2. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
3. PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
Giraudet AL; Kryza D; Hofman M; Moreau A; Fizazi K; Flechon A; Hicks RJ; Tran B
Ther Adv Med Oncol; 2021; 13():17588359211053898. PubMed ID: 34721674
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Advances in Immunotherapies for Hematological Malignancies.
Nogami A; Sasaki K
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232824
[TBL] [Abstract][Full Text] [Related]
5. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
6. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
8. PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model.
Alzubi J; Dettmer-Monaco V; Kuehle J; Thorausch N; Seidl M; Taromi S; Schamel W; Zeiser R; Abken H; Cathomen T; Wolf P
Mol Ther Oncolytics; 2020 Sep; 18():226-235. PubMed ID: 32728611
[TBL] [Abstract][Full Text] [Related]
9. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
10. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
11. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Hernandez-Hoyos G; Sewell T; Bader R; Bannink J; Chenault RA; Daugherty M; Dasovich M; Fang H; Gottschalk R; Kumer J; Miller RE; Ravikumar P; Wiens J; Algate PA; Bienvenue D; McMahan CJ; Natarajan SK; Gross JA; Blankenship JW
Mol Cancer Ther; 2016 Sep; 15(9):2155-65. PubMed ID: 27406985
[TBL] [Abstract][Full Text] [Related]
12. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death.
Wu L; Liu F; Yin L; Wang F; Shi H; Zhao Q; Yang F; Chen D; Dong X; Gu Y; Xing N
Cancer Commun (Lond); 2022 Aug; 42(8):768-783. PubMed ID: 35706368
[TBL] [Abstract][Full Text] [Related]
13. Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond.
Nauseef JT; Bander NH; Tagawa ST
Eur Urol Focus; 2021 Mar; 7(2):254-257. PubMed ID: 33648895
[TBL] [Abstract][Full Text] [Related]
14. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Wong RL; Yu EY
Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
[TBL] [Abstract][Full Text] [Related]
15. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
[TBL] [Abstract][Full Text] [Related]
17. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
18. Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer.
Dorff TB; Narayan V; Forman SJ; Zang PD; Fraietta JA; June CH; Haas NB; Priceman SJ
Clin Cancer Res; 2022 Feb; 28(4):576-584. PubMed ID: 34675084
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in prostate cancer: current state and future perspectives.
Handa S; Hans B; Goel S; Bashorun HO; Dovey Z; Tewari A
Ther Adv Urol; 2020; 12():1756287220951404. PubMed ID: 32952615
[TBL] [Abstract][Full Text] [Related]
20. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
